[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651832":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":43,"studyPopulation":43,"armGroups":50,"interventions":57,"overallOfficials":63,"centralContacts":67,"locations":72,"responsibleParty":87,"collaborators":90,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":43,"studyType":110,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":123,"whyStopped":43,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Chest Diseases Hospital, Ministry of Health, Kuwait","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":43},[9,13],{"measure":10,"description":11,"timeFrame":12},"Consent rate (co-primary outcome P1)","Proportion of eligible individuals approached who consent to participate in screening. Co-primary outcome P1. Overall screening uptake (the proportion of eligible approached individuals who receive an adequate baseline scan, computed on the evaluable cohort) is additionally reported as a descriptive measure in the participant flow diagram.","12 months from start of recruitment",{"measure":14,"description":15,"timeFrame":16},"Baseline LDCT scan completion rate (co-primary outcome P2)","Proportion of consented, evaluable participants who complete a technically adequate baseline LDCT scan within 90 days of consent. The evaluable cohort comprises consented participants whose consent date precedes data lock by at least 90 days (a full 90-day opportunity window); participants consented fewer than 90 days before data lock are excluded from the denominator as not yet evaluable. Participants who withdraw after consent are counted as non-completers. Co-primary outcome P2.","15 months from start of recruitment (12-month recruitment period plus 90-day scan-completion window)",[18,21,25,28,31,34,37,40],{"measure":19,"description":20,"timeFrame":12},"Barriers to screening participation","Reasons for declining screening among eligible individuals, collected with a structured decline questionnaire (categorical response options plus free text), and barrier themes coded from responses. Reported as frequencies and proportions of barrier categories; no scored scale is used for this outcome.",{"measure":22,"description":23,"timeFrame":24},"Lung cancer detection rate and stage distribution","Number and proportion of screen-detected lung cancers, by TNM stage (stage I-II vs III-IV).","24 months from start of recruitment",{"measure":26,"description":27,"timeFrame":12},"Lung-RADS category distribution","Proportion of baseline scans classified as Lung-RADS 1-2, 3, 4A, and 4B\u002F4X.",{"measure":29,"description":30,"timeFrame":24},"Artificial intelligence software performance","Concordance of AI-based nodule detection and Lung-RADS categorization with radiologist reading (sensitivity, specificity, agreement).",{"measure":32,"description":33,"timeFrame":24},"Radiation exposure","Mean effective dose (mSv) per LDCT examination and cumulative effective dose per participant.",{"measure":35,"description":36,"timeFrame":12},"Incidental findings rate","Proportion of scans with clinically significant incidental findings (Lung-RADS modifier S).",{"measure":38,"description":39,"timeFrame":24},"Adherence to recommended follow-up","Proportion of participants completing recommended follow-up imaging (annual round 2, or short-interval CT at 3 or 6 months).",{"measure":41,"description":42,"timeFrame":24},"Participant-reported experience and distress","Participant-reported worry, satisfaction, and psychological distress measured with study questionnaires at baseline, post-CT, results visit, and exit. Lung cancer and radiation worry are single-item scales (range 1-5; higher scores indicate greater worry, a worse outcome). Satisfaction and experience items are 5-point scales (range 1-5; higher scores indicate greater satisfaction, a better outcome). Psychological distress is measured with the Patient Health Questionnaire-4 (PHQ-4; total score range 0-12; higher scores indicate greater anxiety and depression symptoms, a worse outcome).",null,{"allocation":45,"interventionModel":46,"interventionModelDescription":43,"primaryPurpose":47,"observationalModel":43,"timePerspective":43,"maskingInfo":48},"NA","SINGLE_GROUP","SCREENING",{"masking":49,"maskingDescription":43,"whoMasked":43},"NONE",[51],{"label":52,"type":53,"description":54,"interventionNames":55},"LDCT screening","OTHER","All enrolled participants undergo baseline assessment and low-dose CT screening at enrollment and a second round at 12 months (Lung-RADS 1-2), with short-interval CT at 6 or 3 months for Lung-RADS 3 or 4A respectively, and diagnostic work-up\u002Fmultidisciplinary team referral for Lung-RADS 4B-4X. CT images are read by a radiologist and independently analyzed by AI software.",[56],"Procedure: Low-dose computed tomography (LDCT) lung cancer screening",[58],{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":43},"PROCEDURE","Low-dose computed tomography (LDCT) lung cancer screening","Low-dose chest CT without contrast, reported using Lung-RADS. Management and follow-up intervals follow the Lung-RADS category (annual repeat for 1-2; short-interval CT at 6 months for 3 and 3 months for 4A; diagnostic work-up and multidisciplinary team referral for 4B\u002F4X; incidental findings referred per modifier S). All scans are additionally analyzed by artificial intelligence software in parallel with radiologist reading.",[52],[64],{"name":65,"affiliation":5,"role":66},"Sulaiman Khadadah, MD","PRINCIPAL_INVESTIGATOR",[68],{"name":65,"role":69,"phone":70,"phoneExt":43,"email":71},"CONTACT","+96555966111","khadadas@tcd.ie",[73],{"facility":74,"status":43,"city":75,"state":43,"zip":43,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Lung Cancer Screening Clinic, Chest Diseases Hospital","Kuwait City","Kuwait","KW",{"type":79,"coordinates":80},"Point",[81,82],47.97429,29.367,{"lat":82,"lon":81},[85],{"name":86,"role":69,"phone":70,"phoneExt":43,"email":71},"Sulaiman Khadadah",{"type":88,"investigatorFullName":86,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"SPONSOR_INVESTIGATOR","Principal Investigator",[91,93],{"name":92,"class":53},"Kuwait Foundation for the Advancement of Sciences",{"name":94,"class":6},"Ministry of Health, Kuwait","100651832","feasibility-and-uptake-of-low-dose-ct-lung-cancer-screening-in-kuwait-100651832",false,"NCT07766538","Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in Kuwait","ALIA Kuwait: A Prospective Pilot Feasibility Study of Low-Dose Computed Tomography Screening for Lung Cancer in High-Risk Individuals in Kuwait","ALIA","Inclusion Criteria:\n\n* Age 50 to 80 years\n* Smoking history of at least 20 pack-years, totalled across all tobacco products using pre-specified equivalency conventions (1 shisha head-year = 1 pack-year; 1 cigar = 4 cigarettes; 1 pipe bowl = 2.5 cigarettes; roll-your-own tobacco 1 g = 1 cigarette). Current and former smokers are eligible regardless of time since quitting.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous diagnosis of lung cancer\n* Currently under surveillance for pulmonary nodules\n* Currently undergoing diagnostic assessment, treatment, or surveillance for major comorbidities\n* Unable to lie flat with arms raised above the head for CT scanning\n* Symptoms suggestive of lung cancer (persistent or worsening cough, haemoptysis, or unexplained weight loss of more than 7 kg in the past year)",true,"ALL","50 Years","80 Years",{"count":108,"type":109},500,"ESTIMATED","INTERVENTIONAL",[45],"Lung cancer is a leading cause of cancer-related death in Kuwait, where most cases are diagnosed at an advanced stage and there is no national screening program. This prospective pilot feasibility study will offer low-dose computed tomography (LDCT) screening to approximately 500 high-risk individuals aged 50-80 years across Kuwait. The primary objective is to assess the uptake of, and barriers to, LDCT lung cancer screening in Kuwait and to establish a framework for a national screening program. Participants undergo eligibility assessment (smoking history of at least 20 pack-years, totalled across all tobacco products using pre-specified equivalency conversions for shisha\u002Fwaterpipe, cigar, pipe, and roll-your-own tobacco), baseline assessment, LDCT screening with Lung-RADS-based management, a second screening round at 12 months, and follow-up. LDCT images are read by radiologists and in parallel by artificial intelligence (AI) software to evaluate AI-assisted reading. Findings will inform national lung cancer screening guidelines for Kuwait.",[114,115],"Lung Cancer","Lung Neoplasms",[117,118,119,120,121,76,122],"lung cancer screening","low-dose computed tomography","Lung-RADS","artificial intelligence","shisha waterpipe smoking","pilot feasibility study","NOT_YET_RECRUITING","2026-08-14",{"date":126,"type":127},"2026-08-17","ACTUAL",{"date":129,"type":109},"2026-09-01",{"date":131,"type":109},"2029-08-31",{"name":86,"class":6},1]